ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1675

Triptolide Inhibits Th17 Differentation By JAK2/STAT3 Signal Pathway in Inflammation of Ankylosing Spondylitis

Hongxiao Liu1, Junyao Song1, Ziqi Xu1, Xinghua Feng1, Quan Jiang2 and YaNan Zhao3, 1Department of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 2Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 3Department of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, BeiJing, China

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: T cells and ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Th17 plays important role in pathogenesis of AS inflammation, and its main effector, IL-17, was the critical effector on mediating it. Activated of Th17 and IL-17 are both depending on JAK/STAT signal pathway. A cluster of recent papers identify Thunder God Vine as a powerful drug in AS treatment in China, in which Triptolide was demonstrated as the key ingredient in anti-inflammatory. This research aims to explore the role of Triptolide played in Th17 differentiation and AS inflammation by interfering the JAK/STAT.

Methods: 30 AS patients (18-50years) in active stage and 15 healthy controls (18-50years) participated in the experiments. All patients were met with the modified New York criteria(Bath Disease Activity Score>4). PBMCs generated from patients were cultivate with different concentrations of Triptolide for 24 hours (High: 50ng/ml; Medium: 25ng/ml; Low: 12.5ng/ml). The supernate level of IL-17 was detected by ELISA, the protein levels of JAK2/STAT3 signal pathway were detected by Western blotting, and the mRNA level of RORc was detected by quantitative PCR (qPCR).

Results: Compared with controls, the protein expression level of pJak2,pSata3,RORc was higher in AS groups than in normal ones(**p<0.001£©. After the intervention of the triptolide, protein expression level of pJak2,pSata3,RORc was lower than in AS groups.(#p<0.05). ( Figure1)

The transcriptional level of RORc mRNA was higher in AS groups than normal (**p<0.001£©.After the intervention of the triptolide, the transcriptional level of RORc mRNA was lower than in AS groups.(#p<0.05) ( Figure2).     The level of  IL-17 in active AS patients was higher than normal; (**p<0.001);after the intervention of the triptolide,the levels of IL-17 was lower than AS groups . (#p<0.05) ( Figure3).

Conclusion: Our findings showed the suppression of activated JAK2/STAT3 signal pathway and the depression of pJAK2 and pSTAT3 expression by Triptolide. It might be one of the inhibitive factor modulate RORc transcription on one hand, and could be an depressor in IL-17 secretion directly on another. Which suggesting Triptolide may probably regulates Th17 differentiation through JAK2/STAT3 signal pathway. That¡¯s one of molecular mechanism which it plays in relieving AS inflammation. These exciting findings have broad implications for the inhibitor of JAK/STAT signal pathway in AS targeted therapy.


Disclosure: H. Liu, None; J. Song, None; Z. Xu, None; X. Feng, None; Q. Jiang, None; Y. Zhao, None.

To cite this abstract in AMA style:

Liu H, Song J, Xu Z, Feng X, Jiang Q, Zhao Y. Triptolide Inhibits Th17 Differentation By JAK2/STAT3 Signal Pathway in Inflammation of Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/triptolide-inhibits-th17-differentation-by-jak2stat3-signal-pathway-in-inflammation-of-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/triptolide-inhibits-th17-differentation-by-jak2stat3-signal-pathway-in-inflammation-of-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology